The American Medical Association (AMA) is issuing the CPT code update to ensure electronic systems across the U.S. health care system are ready in advance for the potential FDA authorization. The AMA announced an editorial update to Current Procedural Terminology (CPT), including recently assigned provisional CPT codes for COVID-19 booster candidates from Pfizer and Sanofi-GlaxoSmithKline.
Indeed, the CPT Editorial Panel has approved the addition of 35 Category I codes, including three Category I codes to report the Sanofi Pasteur booster vaccine code and its associated administration code, and the Pfizer booster code.
The Sanofi-GSK booster candidate is proposed for use in persons age 18 and older who have completed a COVID-19 vaccine primary series. In contrast, the Pfizer booster candidate is suggested for use in children ages 5 to 11 who have completed a COVID-19 vaccine primary series.
The Administration code for Pfizer booster candidate is :
0074A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose
The product and administration codes for Sanofi-GSK booster candidate are:
91310: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use.
0104A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, booster dose.
To know more about all the new vaccine-specific CPT codes, click HERE